search
Back to results

Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder (ORBITOC3)

Primary Purpose

Obsessive-Compulsive Disorder

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
rTMS Treatment
Sponsored by
Centre Hospitalier Henri Laborit
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obsessive-Compulsive Disorder focused on measuring rTMS, D-B80 A/P

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age: Participants will be both males and females, 18-65 years of age included.
  • diagnosis of OCD
  • all the patients must have failed to respond to at least two different pharmacological treatment used for at least 6 weeks
  • Affiliation to a social security system (recipient or assignee),
  • Signed written inform consent form

Exclusion Criteria:

  • The exclusion criteria are a diagnosis of another psychiatric disorder (except for anxious disorders), a diagnosis of a significant active medical illness, pregnancy or other neurological illness
  • In accordance with the safety criteria for rTMS, patients with a history of seizure or bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips placed inside the skull will also be excluded
  • The patients won't be allowed to change their medication during the trial. The treatment must be stable at least 3 week before day 0.
  • Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception or who is nursing,
  • Patient under curators
  • Patient hospitalized under duress
  • Patient unable to give his or hers informed consent

Sites / Locations

  • Sorbonne University, Pitié-Salpêtrière HospitalRecruiting
  • Centre Hospitalier Henri LaboritRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active stimulation

Sham Stimulation

Arm Description

Active rTMS stimulation , 2 session per day during 10 days.

Sham rTMS stimulation , 2 session per day during 10 days.

Outcomes

Primary Outcome Measures

Yale Brown Obsessive Compulsive Scale score
Significant clinical change (≥ 25%) from baseline to two weeks after the treatment sequence, assessed by a significant reduction in YBOCS scores at day 25

Secondary Outcome Measures

Yale Brown Obsessive Compulsive Scale
Significant clinical change of the YBOCS score (≥25% decrease), from baseline to day 70
general assessement functioning (GAF)
Change of the general assessement functioning (GAF) at day 25
general assessement functioning (GAF)
Change of the general assessement functioning (GAF) at day 70
Clinical Global Impression (CGI)
Clinical Global Impressions (CGI) change at day 25
Clinical Global Impression (CGI)
Clinical Global Impressions (CGI) change at day 70
Adverse events linked to the rTMS treatment
Number and types of adverse events linked to the rTMS treatment

Full Information

First Posted
June 7, 2021
Last Updated
August 18, 2023
Sponsor
Centre Hospitalier Henri Laborit
search

1. Study Identification

Unique Protocol Identification Number
NCT04934007
Brief Title
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
Acronym
ORBITOC3
Official Title
A Randomized Control Trial of Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 6, 2021 (Actual)
Primary Completion Date
August 2, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Henri Laborit

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obsessive-Compulsive Disorder
Keywords
rTMS, D-B80 A/P

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
136 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active stimulation
Arm Type
Experimental
Arm Description
Active rTMS stimulation , 2 session per day during 10 days.
Arm Title
Sham Stimulation
Arm Type
Sham Comparator
Arm Description
Sham rTMS stimulation , 2 session per day during 10 days.
Intervention Type
Device
Intervention Name(s)
rTMS Treatment
Intervention Description
1 Hz rTMS
Primary Outcome Measure Information:
Title
Yale Brown Obsessive Compulsive Scale score
Description
Significant clinical change (≥ 25%) from baseline to two weeks after the treatment sequence, assessed by a significant reduction in YBOCS scores at day 25
Time Frame
baseline and 25 days
Secondary Outcome Measure Information:
Title
Yale Brown Obsessive Compulsive Scale
Description
Significant clinical change of the YBOCS score (≥25% decrease), from baseline to day 70
Time Frame
baseline and 70 days
Title
general assessement functioning (GAF)
Description
Change of the general assessement functioning (GAF) at day 25
Time Frame
baseline and 25 days
Title
general assessement functioning (GAF)
Description
Change of the general assessement functioning (GAF) at day 70
Time Frame
baseline and 70 days
Title
Clinical Global Impression (CGI)
Description
Clinical Global Impressions (CGI) change at day 25
Time Frame
baseline and 25 days
Title
Clinical Global Impression (CGI)
Description
Clinical Global Impressions (CGI) change at day 70
Time Frame
baseline and 70 days
Title
Adverse events linked to the rTMS treatment
Description
Number and types of adverse events linked to the rTMS treatment
Time Frame
70 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: Participants will be both males and females, 18-65 years of age included. diagnosis of OCD all the patients must have failed to respond to at least two different pharmacological treatment used for at least 6 weeks Affiliation to a social security system (recipient or assignee), Signed written inform consent form Exclusion Criteria: The exclusion criteria are a diagnosis of another psychiatric disorder (except for anxious disorders), a diagnosis of a significant active medical illness, pregnancy or other neurological illness In accordance with the safety criteria for rTMS, patients with a history of seizure or bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips placed inside the skull will also be excluded The patients won't be allowed to change their medication during the trial. The treatment must be stable at least 3 week before day 0. Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception or who is nursing, Patient under curators Patient hospitalized under duress Patient unable to give his or hers informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ghina Harika-Germaneau, MD, PhD
Phone
+33 5 16 52 61 18
Email
ghina.harika.germaneau@ch-poitiers.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Nematollah Jaafari, PR
Phone
+33 5 16 52 61 18
Email
nemat.jaafari@ch-poitiers.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ghina Harika-Germaneau
Organizational Affiliation
Centre Hospitalier Henri Laborit
Official's Role
Study Director
Facility Information:
Facility Name
Sorbonne University, Pitié-Salpêtrière Hospital
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruno Millet, PR
Email
b.millet@aphp.fr
Facility Name
Centre Hospitalier Henri Laborit
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ghina Harika-Germaneau, MD, PhD
Phone
+33 5 16 52 61 18
Email
ghina.harika-germaneau@ch-poitiers.fr

12. IPD Sharing Statement

Learn more about this trial

Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder

We'll reach out to this number within 24 hrs